ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)

NCT05279417 PHASE2 COMPLETED

This study evaluates ATI-450 plus MTX versus placebo plus MTX in participants with moderate to severe active RA who have had an inadequate response to MTX alone.

Details

Lead sponsor	Aclaris Therapeutics, Inc.
Phase	PHASE2
Status	COMPLETED
Enrolment	251
Start date	Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Oct 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Rheumatoid Arthritis

Interventions

• ATI-450 50 mg oral tablet BID
• Placebo oral tablet
• Methotrexate
• ATI-450 20 mg oral tablet BID

Countries

United States, Bulgaria, Poland, Czechia